Global Next Generation Cancer Diagnostic Market
Global Next Generation Cancer Diagnostic Market

Next Generation Cancer Diagnostic Comprehensive Study by Application (Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis), Function (Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis), Technology (Next Generation Sequencing, QPCR & Multiplexing, Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR), Protein Microarrays, DNA Microarrays), End User (Academic Institutes & Research Centres, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Other End Users), Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others) Players and Region - Global Market Outlook to 2026

Next Generation Cancer Diagnostic Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2021 Edition 217 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Next Generation Cancer Diagnostic Market Overview:
Development and introduction of product offerings by a number of large entities is a significant factor expected to provide lucrative growth avenues to this market. With accelerating the development of companion diagnostics for their implementation in delivering personalized and advanced genomic medicine, the market is characterized by potentially high-value avenues and opportunities for growth over the forecast period. A cancer diagnosis is done by physical exam, laboratory studies, imaging studies and biopsy. To confirm the diagnosis of most cancers, a biopsy is done in which a tissue sample is removed from the suspected tumor and studied under a microscope to check for cancer cells. Some of the players profiled in the study are GE Healthcare (United States), Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Qiagen (Germany), Novartis AG (Switzerland), Abbott (United States), Thermo Fisher Scientific, Inc. (United States), Opko Health, Inc. (United States), Myriad Genetics, Inc (United States) and Agilent Technologies (United States).

On the basis of geography, the market of Next Generation Cancer Diagnostic has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Function, the sub-segment i.e. Therapeutic Monitoring will boost the Next Generation Cancer Diagnostic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Technology, the sub-segment i.e. Next Generation Sequencing will boost the Next Generation Cancer Diagnostic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Academic Institutes & Research Centres will boost the Next Generation Cancer Diagnostic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Cancer, the sub-segment i.e. Lung Cancer will boost the Next Generation Cancer Diagnostic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Technical Advancement in Next Generation Cancer Diagnostic platform
  • Ability to Provide Cost Effective Solution

Influencing Trend
  • Development in Next Generation Technology
  • Adoption and Integration of Advanced LIMS (Laboratory Information Management System) Real-Time Tracking Method

Restraints
  • Lack of Budget in Emerging Economies
  • Lack of Awareness About Next Generation Cancer Diagnostic Technology

Opportunities
  • Favorable Government Initiatives
  • Incorporation of Big Data

Challenges
  • Issue Related to Ethics
  • Problem Associated With Interpretation of Complex Data




The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Target Audience:
Next generation cancer diagnostic equipment manufacturers, and distributors, Next generation cancer diagnostic service companies, Research laboratories and academic institutes, Research and consulting firms, Healthcare institutions, Pharmaceutical and biotechnology companies, Contract manufacturing organizations (CMOs) and Contract research organizations (CROs)

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Next Generation Cancer Diagnostic market on the basis of product [] , application [Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis and Genetic Analysis], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Next Generation Cancer Diagnostic market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Next Generation Cancer Diagnostic industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Cepheid, PerkinElmer, Genomic Health, Inc. and Illumina, Inc..
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Next Generation Cancer Diagnostic market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Report Objectives / Segmentation Covered
By Application
  • Biomarker Development
  • CTC Analysis
  • Proteomic Analysis
  • Epigenetic Analysis
  • Genetic Analysis
By Function
  • Therapeutic Monitoring
  • Companion Diagnostics
  • Prognostics
  • Cancer Screening
  • Risk Analysis

By Technology
  • Next Generation Sequencing
  • QPCR & Multiplexing
  • Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
  • Protein Microarrays
  • DNA Microarrays

By End User
  • Academic Institutes & Research Centres
  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Other End Users

By Cancer
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Technical Advancement in Next Generation Cancer Diagnostic platform
      • 3.2.2. Ability to Provide Cost Effective Solution
    • 3.3. Market Challenges
      • 3.3.1. Issue Related to Ethics
      • 3.3.2. Problem Associated With Interpretation of Complex Data
    • 3.4. Market Trends
      • 3.4.1. Development in Next Generation Technology
      • 3.4.2. Adoption and Integration of Advanced LIMS (Laboratory Information Management System) Real-Time Tracking Method
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Next Generation Cancer Diagnostic, by Application, Function, Technology, End User, Cancer and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Next Generation Cancer Diagnostic (Value)
      • 5.2.1. Global Next Generation Cancer Diagnostic by: Application (Value)
        • 5.2.1.1. Biomarker Development
        • 5.2.1.2. CTC Analysis
        • 5.2.1.3. Proteomic Analysis
        • 5.2.1.4. Epigenetic Analysis
        • 5.2.1.5. Genetic Analysis
      • 5.2.2. Global Next Generation Cancer Diagnostic by: Function (Value)
        • 5.2.2.1. Therapeutic Monitoring
        • 5.2.2.2. Companion Diagnostics
        • 5.2.2.3. Prognostics
        • 5.2.2.4. Cancer Screening
        • 5.2.2.5. Risk Analysis
      • 5.2.3. Global Next Generation Cancer Diagnostic by: Technology (Value)
        • 5.2.3.1. Next Generation Sequencing
        • 5.2.3.2. QPCR & Multiplexing
        • 5.2.3.3. Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
        • 5.2.3.4. Protein Microarrays
        • 5.2.3.5. DNA Microarrays
      • 5.2.4. Global Next Generation Cancer Diagnostic by: End User (Value)
        • 5.2.4.1. Academic Institutes & Research Centres
        • 5.2.4.2. Hospitals & Clinics
        • 5.2.4.3. Pharmaceutical & Biotechnology Companies
        • 5.2.4.4. Other End Users
      • 5.2.5. Global Next Generation Cancer Diagnostic by: Cancer (Value)
        • 5.2.5.1. Lung Cancer
        • 5.2.5.2. Breast Cancer
        • 5.2.5.3. Colorectal Cancer
        • 5.2.5.4. Cervical Cancer
        • 5.2.5.5. Others
      • 5.2.6. Global Next Generation Cancer Diagnostic Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Next Generation Cancer Diagnostic: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GE Healthcare (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Koninklijke Philips N.V. (Netherlands)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Qiagen (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abbott (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Opko Health, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Myriad Genetics, Inc (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Agilent Technologies (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Next Generation Cancer Diagnostic Sale, by Application, Function, Technology, End User, Cancer and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Next Generation Cancer Diagnostic (Value)
      • 7.2.1. Global Next Generation Cancer Diagnostic by: Application (Value)
        • 7.2.1.1. Biomarker Development
        • 7.2.1.2. CTC Analysis
        • 7.2.1.3. Proteomic Analysis
        • 7.2.1.4. Epigenetic Analysis
        • 7.2.1.5. Genetic Analysis
      • 7.2.2. Global Next Generation Cancer Diagnostic by: Function (Value)
        • 7.2.2.1. Therapeutic Monitoring
        • 7.2.2.2. Companion Diagnostics
        • 7.2.2.3. Prognostics
        • 7.2.2.4. Cancer Screening
        • 7.2.2.5. Risk Analysis
      • 7.2.3. Global Next Generation Cancer Diagnostic by: Technology (Value)
        • 7.2.3.1. Next Generation Sequencing
        • 7.2.3.2. QPCR & Multiplexing
        • 7.2.3.3. Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
        • 7.2.3.4. Protein Microarrays
        • 7.2.3.5. DNA Microarrays
      • 7.2.4. Global Next Generation Cancer Diagnostic by: End User (Value)
        • 7.2.4.1. Academic Institutes & Research Centres
        • 7.2.4.2. Hospitals & Clinics
        • 7.2.4.3. Pharmaceutical & Biotechnology Companies
        • 7.2.4.4. Other End Users
      • 7.2.5. Global Next Generation Cancer Diagnostic by: Cancer (Value)
        • 7.2.5.1. Lung Cancer
        • 7.2.5.2. Breast Cancer
        • 7.2.5.3. Colorectal Cancer
        • 7.2.5.4. Cervical Cancer
        • 7.2.5.5. Others
      • 7.2.6. Global Next Generation Cancer Diagnostic Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Next Generation Cancer Diagnostic: by Application(USD Million)
  • Table 2. Next Generation Cancer Diagnostic Biomarker Development , by Region USD Million (2015-2020)
  • Table 3. Next Generation Cancer Diagnostic CTC Analysis , by Region USD Million (2015-2020)
  • Table 4. Next Generation Cancer Diagnostic Proteomic Analysis , by Region USD Million (2015-2020)
  • Table 5. Next Generation Cancer Diagnostic Epigenetic Analysis , by Region USD Million (2015-2020)
  • Table 6. Next Generation Cancer Diagnostic Genetic Analysis , by Region USD Million (2015-2020)
  • Table 7. Next Generation Cancer Diagnostic: by Function(USD Million)
  • Table 8. Next Generation Cancer Diagnostic Therapeutic Monitoring , by Region USD Million (2015-2020)
  • Table 9. Next Generation Cancer Diagnostic Companion Diagnostics , by Region USD Million (2015-2020)
  • Table 10. Next Generation Cancer Diagnostic Prognostics , by Region USD Million (2015-2020)
  • Table 11. Next Generation Cancer Diagnostic Cancer Screening , by Region USD Million (2015-2020)
  • Table 12. Next Generation Cancer Diagnostic Risk Analysis , by Region USD Million (2015-2020)
  • Table 13. Next Generation Cancer Diagnostic: by Technology(USD Million)
  • Table 14. Next Generation Cancer Diagnostic Next Generation Sequencing , by Region USD Million (2015-2020)
  • Table 15. Next Generation Cancer Diagnostic QPCR & Multiplexing , by Region USD Million (2015-2020)
  • Table 16. Next Generation Cancer Diagnostic Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR) , by Region USD Million (2015-2020)
  • Table 17. Next Generation Cancer Diagnostic Protein Microarrays , by Region USD Million (2015-2020)
  • Table 18. Next Generation Cancer Diagnostic DNA Microarrays , by Region USD Million (2015-2020)
  • Table 19. Next Generation Cancer Diagnostic: by End User(USD Million)
  • Table 20. Next Generation Cancer Diagnostic Academic Institutes & Research Centres , by Region USD Million (2015-2020)
  • Table 21. Next Generation Cancer Diagnostic Hospitals & Clinics , by Region USD Million (2015-2020)
  • Table 22. Next Generation Cancer Diagnostic Pharmaceutical & Biotechnology Companies , by Region USD Million (2015-2020)
  • Table 23. Next Generation Cancer Diagnostic Other End Users , by Region USD Million (2015-2020)
  • Table 24. Next Generation Cancer Diagnostic: by Cancer(USD Million)
  • Table 25. Next Generation Cancer Diagnostic Lung Cancer , by Region USD Million (2015-2020)
  • Table 26. Next Generation Cancer Diagnostic Breast Cancer , by Region USD Million (2015-2020)
  • Table 27. Next Generation Cancer Diagnostic Colorectal Cancer , by Region USD Million (2015-2020)
  • Table 28. Next Generation Cancer Diagnostic Cervical Cancer , by Region USD Million (2015-2020)
  • Table 29. Next Generation Cancer Diagnostic Others , by Region USD Million (2015-2020)
  • Table 30. South America Next Generation Cancer Diagnostic, by Country USD Million (2015-2020)
  • Table 31. South America Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 32. South America Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 33. South America Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 34. South America Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 35. South America Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 36. Brazil Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 37. Brazil Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 38. Brazil Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 39. Brazil Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 40. Brazil Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 41. Argentina Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 42. Argentina Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 43. Argentina Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 44. Argentina Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 45. Argentina Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 46. Rest of South America Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 47. Rest of South America Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 48. Rest of South America Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 49. Rest of South America Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 50. Rest of South America Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 51. Asia Pacific Next Generation Cancer Diagnostic, by Country USD Million (2015-2020)
  • Table 52. Asia Pacific Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 53. Asia Pacific Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 54. Asia Pacific Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 55. Asia Pacific Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 56. Asia Pacific Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 57. China Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 58. China Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 59. China Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 60. China Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 61. China Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 62. Japan Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 63. Japan Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 64. Japan Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 65. Japan Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 66. Japan Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 67. India Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 68. India Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 69. India Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 70. India Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 71. India Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 72. South Korea Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 73. South Korea Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 74. South Korea Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 75. South Korea Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 76. South Korea Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 77. Taiwan Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 78. Taiwan Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 79. Taiwan Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 80. Taiwan Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 81. Taiwan Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 82. Australia Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 83. Australia Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 84. Australia Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 85. Australia Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 86. Australia Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 87. Rest of Asia-Pacific Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 88. Rest of Asia-Pacific Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 89. Rest of Asia-Pacific Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 90. Rest of Asia-Pacific Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 91. Rest of Asia-Pacific Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 92. Europe Next Generation Cancer Diagnostic, by Country USD Million (2015-2020)
  • Table 93. Europe Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 94. Europe Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 95. Europe Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 96. Europe Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 97. Europe Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 98. Germany Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 99. Germany Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 100. Germany Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 101. Germany Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 102. Germany Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 103. France Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 104. France Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 105. France Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 106. France Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 107. France Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 108. Italy Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 109. Italy Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 110. Italy Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 111. Italy Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 112. Italy Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 113. United Kingdom Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 114. United Kingdom Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 115. United Kingdom Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 116. United Kingdom Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 117. United Kingdom Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 118. Netherlands Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 119. Netherlands Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 120. Netherlands Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 121. Netherlands Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 122. Netherlands Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 123. Rest of Europe Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 124. Rest of Europe Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 125. Rest of Europe Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 126. Rest of Europe Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 127. Rest of Europe Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 128. MEA Next Generation Cancer Diagnostic, by Country USD Million (2015-2020)
  • Table 129. MEA Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 130. MEA Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 131. MEA Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 132. MEA Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 133. MEA Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 134. Middle East Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 135. Middle East Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 136. Middle East Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 137. Middle East Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 138. Middle East Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 139. Africa Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 140. Africa Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 141. Africa Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 142. Africa Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 143. Africa Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 144. North America Next Generation Cancer Diagnostic, by Country USD Million (2015-2020)
  • Table 145. North America Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 146. North America Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 147. North America Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 148. North America Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 149. North America Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 150. United States Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 151. United States Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 152. United States Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 153. United States Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 154. United States Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 155. Canada Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 156. Canada Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 157. Canada Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 158. Canada Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 159. Canada Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 160. Mexico Next Generation Cancer Diagnostic, by Application USD Million (2015-2020)
  • Table 161. Mexico Next Generation Cancer Diagnostic, by Function USD Million (2015-2020)
  • Table 162. Mexico Next Generation Cancer Diagnostic, by Technology USD Million (2015-2020)
  • Table 163. Mexico Next Generation Cancer Diagnostic, by End User USD Million (2015-2020)
  • Table 164. Mexico Next Generation Cancer Diagnostic, by Cancer USD Million (2015-2020)
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Company Basic Information, Sales Area and Its Competitors
  • Table 174. Company Basic Information, Sales Area and Its Competitors
  • Table 175. Next Generation Cancer Diagnostic: by Application(USD Million)
  • Table 176. Next Generation Cancer Diagnostic Biomarker Development , by Region USD Million (2021-2026)
  • Table 177. Next Generation Cancer Diagnostic CTC Analysis , by Region USD Million (2021-2026)
  • Table 178. Next Generation Cancer Diagnostic Proteomic Analysis , by Region USD Million (2021-2026)
  • Table 179. Next Generation Cancer Diagnostic Epigenetic Analysis , by Region USD Million (2021-2026)
  • Table 180. Next Generation Cancer Diagnostic Genetic Analysis , by Region USD Million (2021-2026)
  • Table 181. Next Generation Cancer Diagnostic: by Function(USD Million)
  • Table 182. Next Generation Cancer Diagnostic Therapeutic Monitoring , by Region USD Million (2021-2026)
  • Table 183. Next Generation Cancer Diagnostic Companion Diagnostics , by Region USD Million (2021-2026)
  • Table 184. Next Generation Cancer Diagnostic Prognostics , by Region USD Million (2021-2026)
  • Table 185. Next Generation Cancer Diagnostic Cancer Screening , by Region USD Million (2021-2026)
  • Table 186. Next Generation Cancer Diagnostic Risk Analysis , by Region USD Million (2021-2026)
  • Table 187. Next Generation Cancer Diagnostic: by Technology(USD Million)
  • Table 188. Next Generation Cancer Diagnostic Next Generation Sequencing , by Region USD Million (2021-2026)
  • Table 189. Next Generation Cancer Diagnostic QPCR & Multiplexing , by Region USD Million (2021-2026)
  • Table 190. Next Generation Cancer Diagnostic Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR) , by Region USD Million (2021-2026)
  • Table 191. Next Generation Cancer Diagnostic Protein Microarrays , by Region USD Million (2021-2026)
  • Table 192. Next Generation Cancer Diagnostic DNA Microarrays , by Region USD Million (2021-2026)
  • Table 193. Next Generation Cancer Diagnostic: by End User(USD Million)
  • Table 194. Next Generation Cancer Diagnostic Academic Institutes & Research Centres , by Region USD Million (2021-2026)
  • Table 195. Next Generation Cancer Diagnostic Hospitals & Clinics , by Region USD Million (2021-2026)
  • Table 196. Next Generation Cancer Diagnostic Pharmaceutical & Biotechnology Companies , by Region USD Million (2021-2026)
  • Table 197. Next Generation Cancer Diagnostic Other End Users , by Region USD Million (2021-2026)
  • Table 198. Next Generation Cancer Diagnostic: by Cancer(USD Million)
  • Table 199. Next Generation Cancer Diagnostic Lung Cancer , by Region USD Million (2021-2026)
  • Table 200. Next Generation Cancer Diagnostic Breast Cancer , by Region USD Million (2021-2026)
  • Table 201. Next Generation Cancer Diagnostic Colorectal Cancer , by Region USD Million (2021-2026)
  • Table 202. Next Generation Cancer Diagnostic Cervical Cancer , by Region USD Million (2021-2026)
  • Table 203. Next Generation Cancer Diagnostic Others , by Region USD Million (2021-2026)
  • Table 204. South America Next Generation Cancer Diagnostic, by Country USD Million (2021-2026)
  • Table 205. South America Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 206. South America Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 207. South America Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 208. South America Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 209. South America Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 210. Brazil Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 211. Brazil Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 212. Brazil Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 213. Brazil Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 214. Brazil Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 215. Argentina Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 216. Argentina Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 217. Argentina Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 218. Argentina Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 219. Argentina Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 220. Rest of South America Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 221. Rest of South America Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 222. Rest of South America Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 223. Rest of South America Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 224. Rest of South America Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 225. Asia Pacific Next Generation Cancer Diagnostic, by Country USD Million (2021-2026)
  • Table 226. Asia Pacific Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 227. Asia Pacific Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 228. Asia Pacific Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 229. Asia Pacific Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 230. Asia Pacific Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 231. China Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 232. China Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 233. China Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 234. China Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 235. China Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 236. Japan Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 237. Japan Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 238. Japan Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 239. Japan Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 240. Japan Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 241. India Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 242. India Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 243. India Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 244. India Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 245. India Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 246. South Korea Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 247. South Korea Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 248. South Korea Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 249. South Korea Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 250. South Korea Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 251. Taiwan Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 252. Taiwan Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 253. Taiwan Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 254. Taiwan Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 255. Taiwan Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 256. Australia Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 257. Australia Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 258. Australia Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 259. Australia Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 260. Australia Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 261. Rest of Asia-Pacific Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 262. Rest of Asia-Pacific Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 263. Rest of Asia-Pacific Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 264. Rest of Asia-Pacific Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 265. Rest of Asia-Pacific Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 266. Europe Next Generation Cancer Diagnostic, by Country USD Million (2021-2026)
  • Table 267. Europe Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 268. Europe Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 269. Europe Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 270. Europe Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 271. Europe Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 272. Germany Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 273. Germany Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 274. Germany Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 275. Germany Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 276. Germany Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 277. France Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 278. France Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 279. France Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 280. France Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 281. France Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 282. Italy Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 283. Italy Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 284. Italy Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 285. Italy Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 286. Italy Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 287. United Kingdom Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 288. United Kingdom Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 289. United Kingdom Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 290. United Kingdom Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 291. United Kingdom Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 292. Netherlands Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 293. Netherlands Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 294. Netherlands Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 295. Netherlands Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 296. Netherlands Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 297. Rest of Europe Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 298. Rest of Europe Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 299. Rest of Europe Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 300. Rest of Europe Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 301. Rest of Europe Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 302. MEA Next Generation Cancer Diagnostic, by Country USD Million (2021-2026)
  • Table 303. MEA Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 304. MEA Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 305. MEA Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 306. MEA Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 307. MEA Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 308. Middle East Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 309. Middle East Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 310. Middle East Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 311. Middle East Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 312. Middle East Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 313. Africa Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 314. Africa Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 315. Africa Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 316. Africa Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 317. Africa Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 318. North America Next Generation Cancer Diagnostic, by Country USD Million (2021-2026)
  • Table 319. North America Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 320. North America Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 321. North America Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 322. North America Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 323. North America Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 324. United States Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 325. United States Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 326. United States Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 327. United States Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 328. United States Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 329. Canada Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 330. Canada Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 331. Canada Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 332. Canada Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 333. Canada Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 334. Mexico Next Generation Cancer Diagnostic, by Application USD Million (2021-2026)
  • Table 335. Mexico Next Generation Cancer Diagnostic, by Function USD Million (2021-2026)
  • Table 336. Mexico Next Generation Cancer Diagnostic, by Technology USD Million (2021-2026)
  • Table 337. Mexico Next Generation Cancer Diagnostic, by End User USD Million (2021-2026)
  • Table 338. Mexico Next Generation Cancer Diagnostic, by Cancer USD Million (2021-2026)
  • Table 339. Research Programs/Design for This Report
  • Table 340. Key Data Information from Secondary Sources
  • Table 341. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Next Generation Cancer Diagnostic: by Application USD Million (2015-2020)
  • Figure 5. Global Next Generation Cancer Diagnostic: by Function USD Million (2015-2020)
  • Figure 6. Global Next Generation Cancer Diagnostic: by Technology USD Million (2015-2020)
  • Figure 7. Global Next Generation Cancer Diagnostic: by End User USD Million (2015-2020)
  • Figure 8. Global Next Generation Cancer Diagnostic: by Cancer USD Million (2015-2020)
  • Figure 9. South America Next Generation Cancer Diagnostic Share (%), by Country
  • Figure 10. Asia Pacific Next Generation Cancer Diagnostic Share (%), by Country
  • Figure 11. Europe Next Generation Cancer Diagnostic Share (%), by Country
  • Figure 12. MEA Next Generation Cancer Diagnostic Share (%), by Country
  • Figure 13. North America Next Generation Cancer Diagnostic Share (%), by Country
  • Figure 14. Global Next Generation Cancer Diagnostic share by Players 2020 (%)
  • Figure 15. Global Next Generation Cancer Diagnostic share by Players (Top 3) 2020(%)
  • Figure 16. Global Next Generation Cancer Diagnostic share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 19. GE Healthcare (United States) Revenue: by Geography 2020
  • Figure 20. Koninklijke Philips N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 21. Koninklijke Philips N.V. (Netherlands) Revenue: by Geography 2020
  • Figure 22. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2020
  • Figure 24. Qiagen (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Qiagen (Germany) Revenue: by Geography 2020
  • Figure 26. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 28. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 29. Abbott (United States) Revenue: by Geography 2020
  • Figure 30. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2020
  • Figure 32. Opko Health, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Opko Health, Inc. (United States) Revenue: by Geography 2020
  • Figure 34. Myriad Genetics, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 35. Myriad Genetics, Inc (United States) Revenue: by Geography 2020
  • Figure 36. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 37. Agilent Technologies (United States) Revenue: by Geography 2020
  • Figure 38. Global Next Generation Cancer Diagnostic: by Application USD Million (2021-2026)
  • Figure 39. Global Next Generation Cancer Diagnostic: by Function USD Million (2021-2026)
  • Figure 40. Global Next Generation Cancer Diagnostic: by Technology USD Million (2021-2026)
  • Figure 41. Global Next Generation Cancer Diagnostic: by End User USD Million (2021-2026)
  • Figure 42. Global Next Generation Cancer Diagnostic: by Cancer USD Million (2021-2026)
  • Figure 43. South America Next Generation Cancer Diagnostic Share (%), by Country
  • Figure 44. Asia Pacific Next Generation Cancer Diagnostic Share (%), by Country
  • Figure 45. Europe Next Generation Cancer Diagnostic Share (%), by Country
  • Figure 46. MEA Next Generation Cancer Diagnostic Share (%), by Country
  • Figure 47. North America Next Generation Cancer Diagnostic Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • GE Healthcare (United States)
  • Koninklijke Philips N.V. (Netherlands)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Qiagen (Germany)
  • Novartis AG (Switzerland)
  • Abbott (United States)
  • Thermo Fisher Scientific, Inc. (United States)
  • Opko Health, Inc. (United States)
  • Myriad Genetics, Inc (United States)
  • Agilent Technologies (United States)
Additional players considered in the study are as follows:
Cepheid , PerkinElmer , Genomic Health, Inc. , Illumina, Inc.
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation